Veklury now available directly from distributor in USA

2 October 2020

Beginning October 1, American hospitals are able to purchase US biotech firm Gilead Sciences’ (Nasdaq: GILD) Veklury (remdesivir) directly from the drug’s authorized, which is distributor, AmerisourceBergen.

Veklury is an antiviral drug currently authorized for emergency use by healthcare providers to treat hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19. Over the past five months, the US government has overseen the allocation and distribution of Veklury due to drug’s limited supply to ensure fair and equitable distribution to COVID-19 patients.

“In the months since Veklury showed promise against COVID-19, President Trump secured the vast majority of the manufacturer’s supplies for the American people, part of the administration’s work to manage scarce resources needed for fighting COVID-19,” said US Department of Health and Human Services (HHS) Secretary Alex Azar.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK